

**INDEPENDENT AUDITORS' REPORT  
AND  
FINANCIAL STATEMENTS  
OF  
SUN PHARMACEUTICALS (EZ) LIMITED**

**AS AT AND FOR THE YEAR ENDED 31 MARCH 2022**



**AHMED MASHUQUE & CO.,** *Chartered Accountants*

---

Navana Obaid Eternia  
28-29 Kakrail (Level # 5,13 &14)  
VIP Road, Dhaka-1000, Bangladesh  
Tel : +880-2-58316931-39, Fax : +880-2-58316929  
Email: [info@ahmedmashuque.com](mailto:info@ahmedmashuque.com), [Web : www.ahmedmashuque.com](http://www.ahmedmashuque.com)  
Member Firm of **Crowe Global**



**INDEPENDENT AUDITOR'S REPORT  
to the shareholders of  
Sun Pharmaceuticals (EZ) Limited**

**Report on the Audit of the Financial Statements**

**Opinion**

We have audited the financial statements of Sun Pharmaceuticals (EZ) Limited (the Company), which comprise the statement of financial position as at 31 March 2022, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as at 31 March 2022, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs).

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), and we have fulfilled our ethical responsibilities in accordance with the IESBA Code and the Institute of Chartered Accountants of Bangladesh (ICAB) Bye Laws. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Responsibilities of Management and Those Charged with Governance for the Financial Statements**

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with IFRSs, the Companies Act, 1994 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

**Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.



As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, But not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

#### **Report on Other Legal and Regulatory Requirements**

In accordance with the Companies Act, 1994 we also report the following:

- a) we have obtained all the information and explanation which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) in our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of those books; and
- c) the statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of account.

**Dated: 12 May 2022**  
**Dhaka**

**Ahmed Mashuque & Co.**  
**Chartered Accountants**  
Mashuque Ahmed FCA  
Senior Partner and CEO  
Enrolment number: 0690  
DVC:

**SUN PHARMACEUTICALS (EZ) LIMITED**

**Statement of financial position**

As at 31 March 2022

Particulars	Notes	Amount in Taka	
		31-Mar-22	31-Mar-21
<b>Assets</b>			
<b>Non current assets</b>			
Capital work-in-progress	4.00	100,155,910	323,123
Right-of-use asset	5.00	189,017,129	199,188,453
<b>Total non current assets</b>		<b>289,173,039</b>	<b>199,511,576</b>
<b>Current assets</b>			
Advances, deposits and prepayments	6.00	83,819,083	35,180,338
Cash and cash equivalents	7.00	64,484,612	15,937,117
<b>Total current assets</b>		<b>148,283,695</b>	<b>51,097,455</b>
<b>Total assets</b>		<b>437,456,734</b>	<b>250,609,031</b>
<b>Shareholder's equity and liabilities</b>			
<b>Shareholder's equity</b>			
Share capital	8.00	60,000,000	60,000,000
Retained earnings		(47,871,641)	(13,705,936)
<b>Total shareholder's equity</b>		<b>12,128,359</b>	<b>46,294,064</b>
<b>Liabilities</b>			
<b>Non current liabilities</b>			
Loan from parent company	9.00	220,000,000	-
Lease liability	10.00	200,848,209	202,254,061
<b>Total non current liabilities</b>		<b>420,848,209</b>	<b>202,254,061</b>
<b>Current liabilities</b>			
Lease liability	10.00	1,405,872	1,272,613
Liabilities for expenses	11.00	3,074,295	788,273
<b>Total current liabilities</b>		<b>4,480,167</b>	<b>2,060,886</b>
<b>Total liabilities</b>		<b>425,328,376</b>	<b>204,314,967</b>
<b>Total shareholder's equity and liabilities</b>		<b>437,456,734</b>	<b>250,609,031</b>

*These financial statements should be read in conjunction with the annexed notes.*

Managing Director

Finance Controller

Director

*Signed in terms of our report of even date annexed.*

Dated: 12 May 2022  
Dhaka.

**Ahmed Mashuque & Co.**  
**Chartered Accountants**  
Mashuque Ahmed FCA  
Senior Partner and CEO  
Enrolment number: 0690  
DVC:

**SUN PHARMACEUTICALS (EZ) LIMITED**  
**Statement of profit or loss and other comprehensive income**  
For the year ended 31 March 2022

Particulars	Notes	Amount in Taka	
		01 April 2021 to 31 March 2022	25 October 2020 to 31 March 2021
Revenue		-	-
Less: Cost of goods sold		-	-
<b>Gross profit</b>		-	-
<b>Less: Expenditures</b>		<b>13,870,315</b> ₳	<b>5,218,191</b> ₳
Operating and other expenses	12.00	3,698,991 ₳	980,138 ₳
Depreciation on Right of use assets (RoU)		10,171,324 ₳	4,238,053 ₳
<b>Profit/(loss) from operations</b>		<b>(13,870,315)</b> ₳	<b>(5,218,191)</b> ₳
Less: Interest expense- lease liability		20,295,390	8,487,745 ₳
<b>Profit/(loss) before income tax</b>		<b>(34,165,705)</b> ₳	<b>(13,705,936)</b> ₳
Income tax		-	-
<b>Net profit/(loss) after income tax</b>		<b>(34,165,705)</b>	<b>(13,705,936)</b> ₳
Other comprehensive income		-	-
<b>Total comprehensive income</b>		<b>(34,165,705)</b> ₳	<b>(13,705,936)</b> ₳

*These financial statements should be read in conjunction with the annexed notes.*

Managing Director

Finance Controller

Director

*Signed in terms of our report of even date annexed.*

Dated: 12 May 2022  
Dhaka.

**Ahmed Mashuque & Co.**  
**Chartered Accountants**  
Mashuque Ahmed FCA  
Senior Partner and CEO  
Enrolment number: 0690  
DVC:

**SUN PHARMACEUTICALS (EZ) LIMITED**  
**Statement of changes in equity**  
For the year ended 31 March 2022

Particulars	Amount in Taka		
	Share capital	Retained earnings	Total
Balance as at 25 October 2020	-	-	-
Addition during the period	60,000,000	-	60,000,000
Addition during the period	-	(13,705,936)	(13,705,936)
<b>Balance as at 31 March 2021</b>	<b>60,000,000</b>	<b>(13,705,936)</b>	<b>46,294,064</b>
Balance as at 01 April 2021	60,000,000	(13,705,936)	46,294,064
Addition during the period		(34,165,705)	(34,165,705)
<b>Balance as at 31 March 2022</b>	<b>60,000,000</b>	<b>(47,871,641)</b>	<b>12,128,359</b>

*These financial statements should be read in conjunction with the annexed notes.*

**Managing Director**

**Finance Controller**

**Director**

**Dated: 12 May 2022**  
**Dhaka.**

**SUN PHARMACEUTICALS (EZ) LIMITED**  
**Statement of cash flows**  
For the year ended 31 March 2022

Particulars	Amount in Taka 01 April 2021 to 31 March 2022	Amount in Taka 25 October 2020 to 31 March 2021
<b>Cash flows from operating activities</b>		
Payments for expenses	148,360,282	(43,739,760)
<b>Net cash generated by/(used in) operating activities (A)</b>	<b>148,360,282</b>	<b>(43,739,760)</b>
<b>Cash flows from investing activities</b>		
Capital work-in-progress	(99,832,787)	(323,123)
<b>Net cash provided by/(used in) investing activities (B)</b>	<b>(99,832,787)</b>	<b>(323,123)</b>
<b>Cash flows from financing activities</b>		
Share capital	-	60,000,000
<b>Net cash provided by/(used in) financing activities (C)</b>	<b>-</b>	<b>60,000,000</b>
<b>Net changes in cash and cash equivalents (A+B+C)</b>	<b>48,527,495</b>	<b>15,937,117</b>
Cash and cash equivalents at the beginning of the year	15,937,117	-
<b>Cash and cash equivalents at the end of the year</b>	<b>64,464,612</b>	<b>15,937,117</b>

*These financial statements should be read in conjunction with the annexed notes.*

Managing Director

Finance Controller

Director

Dated: 12 May 2022  
Dhaka.

**SUN PHARMACEUTICALS (EZ) LIMITED**  
**Notes, Comprising Significant accounting policies and other explanatory information**  
As at 31 March 2022 and for the year ended 31 March 2022

**1.00 Company profile**

**1.01 Legal status of the company**

Sun Pharmaceuticals (EZ) Limited is a private limited company incorporated in 2020 in Bangladesh under the Companies Act, 1994 with an authorized capital of Tk. 250 millions divided into 2,500,000 ordinary shares of Tk 100 each.

**1.02 Address of the Registered office**

The registered office of the Company is located at 14th Floor, Police Plaza Concord (Tower-B), Gulshan-1, Dhaka

**1.03 Nature of business**

The company produces various pharmaceutical products, which are sold in the local market. The operation of the company is yet to start.

**2.00 Basis of preparation**

**2.01 Statement of compliance**

These financial statements have been prepared and the disclosure of information are made in accordance with International Accounting Standards (IASs) and the International Financial Reporting Standards (IFRS) as adopted in Bangladesh by the Financial Reporting Council (FRC), the Companies Act 1994, and other relevant local Laws as applicable. The statement of financial position and the statement of profit or loss and other comprehensive income have been prepared according to International Accounting Standard (IAS) 1: *Presentation of Financial Statements* on accrual basis of accounting following going concern assumption under generally accepted accounting principles.

**Application of International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs)**

IASs or IFRSs	Name of IASs or IFRSs
IAS-1	Presentation of Financial Statements
IAS-7	Statement of Cash Flows
IAS-8	Accounting Policies, Changes in Accounting Estimates and Errors
IAS-10	Events after the Reporting Period
IAS-12	Income Taxes
IAS-16	Property, Plant and Equipment
IAS-19	Employee Benefits
IAS-21	The Effects of Changes in Foreign Exchange Rates
IAS-32	Financial Instruments: Presentation
IAS-37	Provisions, Contingent Liabilities and Contingent Assets
IFRS-7	Financial Instruments: Disclosures
IFRS-15	Revenue from Contracts with Customer
IFRS-16	Leases

**2.02 Reporting period**

The financial period of the company has been determined to be from 01 April to 31 March each year. These financial statements cover one year from 01 April 2021 to 31 March 2022.

**2.03 Basis of accounting**

The financial statements have been prepared under the accrual basis of accounting.

**2.04 Going concern**

The financial statements have been prepared on going concern basis. As per the management assessment, there is no material uncertainties related to events or conditions which may cast significant doubt upon the companies ability to continue as a going concern.

**2.05 Basis of measurement**

The financial statements have been prepared under the historical cost convention.

**2.06 Date of authorisation for issue of financial statements**

The Board of Directors has authorised these financial statements on 12 May 2022.



## **2.07 Directors' responsibility statement**

The Board of Directors takes the responsibility for the preparation and fair presentation of these financial statements.

## **2.08 Use of estimates and judgment**

The preparation of financial statements in conformity with IFRSs requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that year, or in the period of revision and future periods if the revision affects both current and future periods.

## **2.09 Functional and presentational currency and level of precision**

The financial statements are presented in Bangladesh Taka (BDT) currency, which is the Company's functional currency. All financial information presented in BDT has been rounded off to the nearest Taka.

## **2.10 Components of financial statements**

The financial statements comprises of:

- (i) Statement of financial position as at 31 March 2022;
- (ii) Statement of profit or loss and other comprehensive income for the year ended 31 March 2022;
- (iii) Statement of changes in equity for the year ended 31 March 2022;
- (iv) Statement of cash flows for the year ended 31 March 2022; and
- (v) A summary of significant accounting policies and other explanatory information as at 31 March 2022 and for the year ended 31 March 2022.

## **3.00 Significant accounting policies**

### **3.01 Property, plant and equipment**

#### **a) Recognition and measurement**

Property, plant and equipments are stated at cost net of accumulated depreciation. Cost includes expenditures that are directly attributable to the acquisition of the assets.

#### **b) Subsequent cost**

The cost of replacing component of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits are embodied within the component will flow to the company and its cost can be measured reliably. The costs of the day to day servicing of Property, plant and equipments are recognized in the statement of profit and loss and other comprehensive income as incurred.

#### **c) Depreciation**

Depreciation is provided to amortise the cost of the assets after commissioning, over the period of their expected useful lives in accordance with IAS-16.

#### **d) Retirements and Disposals**

On disposal of Property, plant and equipment, the cost and accumulated depreciation are eliminated and gain or loss on such disposal is reflected in the income statement, which is determined with reference to the net book value of the assets and net sales proceeds.

### **3.02 Capital work in progress (CWIP)**

Capital work in progress (CWIP) represents property, plant and equipments under installation/under development as at the balance sheet date. The asset will be transferred to Property plant and equipments when it meets the criteria in accordance with IAS-16: Property plant and equipments.

### **3.03 Right to use assets and lease liability**

The Company is required to adopt IFRS 16 Leases.

IFRS 16 introduces a single, on-balance sheet lease accounting model for lessees. A lessee recognises a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. There are recognition exemptions for short-term leases and leases of low-value items. Lessor accounting remains similar to the current standard – i.e. lessors continue to classify leases as finance or operating leases.

IFRS 16 replaces existing leases guidance, including IAS 17 Leases, IFRIC 4 Determining whether an Arrangement contains a Lease, SIC-15 Operating Leases – Incentives and SIC-27 Evaluating the Substance of Transactions in determining the Legal Form of a Lease.

#### Recognition

A right-of-use asset and a lease liability is recognised by the company at the commencement date.

#### Measurement

##### Initial measurement of the right-of-use asset

At the commencement date, the right-of-use asset are measured at cost.

The cost of the right-of-use asset comprise:

- the amount of the initial measurement of the lease liability,
- any lease payments made at or before the commencement date, less any *lease incentives* received,
- any *initial direct costs* incurred by the lessee; and
- an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset, restoring the site on which it is located or restoring the underlying asset to the condition required by the terms and conditions of the lease, unless those costs are incurred to produce inventories. The lessee incurs the obligation for those costs either at the commencement date or as a consequence of having used the underlying asset during a particular period.

##### Initial measurement of the lease liability

At the commencement date, the lease liabilities are measured at the present value of the lease payments that are not paid at that date. The lease payments are discounted using the *interest rate implicit in the lease/incremental borrowing rate* which is 10%

##### Subsequent measurement of the right-of-use asset

After the commencement date, the right-of-use asset are measured applying a cost model.

The straight-line depreciation is applying as per requirements in IAS 16 *Property, Plant and Equipment* is applied in depreciating the right-of-use asset.

IAS 36 *Impairment of Assets* is applied to determine whether the right-of-use asset is impaired and to account for any impairment loss identified.

##### Subsequent measurement of the lease liability

After the commencement date, the lease liabilities are measured by:

- increasing the carrying amount to reflect interest on the lease liability
- reducing the carrying amount to reflect the lease payments made; and
- remeasuring the carrying amount to reflect any reassessment or lease modifications, or to reflect revised in-substance fixed lease payments

##### Details impact of lease are as under

	Note	Amount
RoU assets as on 31 March 2022	5	189,017,129
Lease Liability	10	202,254,081
Depreciation of RoU		10,171,324
Interest on Lease		20,295,390
Actual rent expense		21,568,003

### 3.04 Inventories

Inventories are stated at the lower of cost and their corresponding net realisable value in accordance with IAS-2 "Inventories". Method used for valuation of inventory of Raw and Packing material is Specific identification method. Cost of finished stocks and work in progress are arrived by using FIFO costing method including allocation of manufacturing overheads related to bringing the inventories to their present condition. Net realisable value is based on estimated selling price less any further costs expected to be incurred to make the sale.

### 3.05 Trade and receivables

Trade receivables are stated net of provisions.

### 3.06 Statement of Cash flows

Statement of Cash flows is prepared in accordance with IAS-7:Statement of cash flows under direct method.

### 3.07 Cash and cash equivalents

Cash and cash equivalents consist of cash in hand, bank deposits and investment in Fixed deposit which were held and available for use by the company without any restriction.

### **3.08 Advances, Deposits and Prepayments**

Advances are initially measured at cost. After initial recognition, advances are carried at cost less deductions, adjustments or charges to other heads of accounts.

Deposits are measured at payment value.

Prepayments are initially measured at cost. After initial recognition, prepayments are carried at cost less charges to the statement of profit or loss and other comprehensive income.

### **3.09 Provisions, Contingent Liabilities and Contingent Assets**

#### **Provisions**

Provision are recognized under IAS- 37, when the Consortium has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefit will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

#### **Contingent assets**

Contingent assets is a possible assets that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the company. The management does not recognise any contingent assets in compliance with IAS-37.

#### **Contingent liabilities**

A contingent liability is a possible obligations that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity or a present obligation that arises from past events but it is not recognised as it is not probable that an outflow of resources emodying economic benefits will be required to settle the obligation or the amount of obligation can not be measured reliably. The management does not recognise any contingent liability in compliance with IAS-37.

### **3.10 Payables and accruals**

Liabilites are recognized for amounts to be paid in future for goods and services received whether or not billed to the company.

### **3.11 Revenue recognition**

The Company has applied IFRS 15 "Revenue from Contracts with Customers" for annual reporting periods beginning on or after 01 January 2018. IFRS 15 provides a single, principles-based approach to the recognition of revenue from all contracts with customers. It focuses on the identification of performance obligations in a contract and requires revenue to be recognized when or as those performance obligations are satisfied.

\*The new standard is based on A new five-step process must be applied before revenue from contract with customer can be recognized:

- i. Identify the contracts with customers;
- ii. Identify the separate performance obligation;
- iii. Determine the transaction price of the contract;
- iv. Allocate the transaction price to each of the separate performance obligations; and
- v. Recognize the revenue as each performance obligation is satisfied.

### **3.12 Foreign currency translations**

Transactions denominated in foreign currencies are translated into Bangladesh taka at the rate of exchange ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated into Bangladesh taka at the exchange rates ruling at the Statement of financial position. Non monetary assets and liabilities denominated in foreign currencies, which are stated at historical cost, are translated into Bangladesh taka at the exchange rate ruling at the date of the transaction. Foreign exchange differences arising on translation are recognized in the Statement of profit or loss and other comprehensive income.

### **3.13 Income tax expense**

Income tax expenses comprises current tax which is recognised in profit or loss except to the extent that its relates to items recognised directly in equity in which case it is recognized in equity.

#### **Exemption of current tax:**

The company is enjoying tax benefit under SRO No 104-Law/Income Tax/2020 Date: 25 March, 2020

### **3.14 Earning per share**

The company has adopted the standard in accordance with IAS 33: Earning per share, which has

**Basic earnings**

This represents earnings for the year attributable to ordinary shareholders. As there were no preference shares requiring returns or dividends, minority interest or extraordinary items, the net profit after tax for the year has been considered as fully attributable to the ordinary shareholders.

**Diluted earnings per share**

No diluted EPS is required to be calculated for the year as there was no scope for dilution during the year under review.

**3.15 Employee benefit scheme**

The company has accounted for and disclosed employee benefits in compliance with the provisions of *IAS 19: Employee Benefits*. The cost of employee benefits is charged off as revenue expenditure in the period to which the contributions relate.

The company's employee benefits include the following:

**Short-term employee benefits**

Short-term employee benefits include salaries, bonuses, leave encashment, etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

**3.16 Events after the reporting date**

In accordance with IAS 10: Events after the reporting period, amount recognized in the financial statements are adjusted for event after the reporting period that provide additional evidence of conditions that existed at the end of the reporting period. No adjustment is given in the financial statements for events after the reporting period that are indicative of conditions that arose after the reporting period. Material non-adjusting events are disclosed in the financial statements.

**3.17 Comparative figures**

The financial statements provides Comparative information in respects of the previous period for all amount reported in the current year financial statements. Comparative figures have been rearranged wherever considered necessary to ensure better comparability with the current year without causing any impact on the profit and value of assets and liabilities as reported in the financial statements.

**3.18 Advances, Deposits and Prepayments**

Advances are initially measured at cost. After initial recognition, advances are carried at cost less deductions, adjustments or charges to other heads of accounts.

Deposits are measured at payment value.

Prepayments are initially measured at cost. After initial recognition, prepayments are carried at cost less charges to the statement of profit or loss and other comprehensive income.

	Amount in Taka	
	31-Mar-22	31-Mar-21
<b>4.00 Capital work-in-progress</b>		
Opening balance	323,123	-
Addition during the year	99,832,767	323,123
Capitalized during the year	-	-
<b>Closing balance</b>	<b>100,155,910</b>	<b>323,123</b>
<b>5.00 Right-of-use asset</b>		
Initial recognition of right to use assets	203,426,505	203,426,505
Accumulated depreciation on RoU	(14,409,376)	(4,238,052)
<b>Closing balance</b>	<b>189,017,129</b>	<b>199,188,453</b>
<i>"The company has already adopted IFRS 16 Leases and the above 'Right to use assets' created against lease contracts. Detail requirements described in Note 3.02."</i>		
<b>6.00 Advances, deposits and prepayments</b>		
<b>Advance :</b>		
Advances to suppliers and others	57,620,906	-
	<b>57,620,906</b>	-
<b>Deposits:</b>		
Security deposits	21,568,003	21,568,003
	<b>21,568,003</b>	<b>21,568,003</b>
<b>Prepayments:</b>		
Prepaid rent & service charge	-	13,592,335
Prepaid Insurance	4,630,174	-
	<b>4,630,174</b>	<b>13,592,335</b>
<b>Total</b>	<b>83,819,083</b>	<b>35,160,338</b>
<b>7.00 Cash and cash equivalents</b>		
<b>Cash in hand</b>	935,000	-
	<b>935,000</b>	-
<b>Cash at bank :</b>		
Citi bank	63,529,612	15,937,117
	<b>63,529,612</b>	<b>15,937,117</b>
<b>Total</b>	<b>64,464,612</b>	<b>15,937,117</b>
<b>8.00 Share capital</b>		
<b>Authorized Capital</b>	<b>250,000,000</b>	<b>250,000,000</b>
(2,500,000 ordinary shares of TK. 100 each)		
<b>Issued, subscribed &amp; paid up share capital</b>	<b>60,000,000</b>	<b>60,000,000</b>
(600,000 ordinary shares of TK. 100 each)		
<b>Share holder position of the company is as under:</b>		
<b>Sun Pharmaceutical (Bangladesh) Limited</b>	59,999,900	59,999,900
(599,999 ordinary shares @ Tk. 100 each)		
<b>Mr. Shuvojit Ghosh</b>	100	100
(01 ordinary shares @ Tk. 100 each)		
<b>Total</b>	<b>60,000,000</b>	<b>60,000,000</b>
<b>9.00 Loan from parent company</b>		
Sun Pharmaceuticals (Bangladesh) Ltd.	220,000,000	-
	<b>220,000,000</b>	-
The amount of loan has been received through banking channel.		
<b>10.00 Lease liability</b>		
Non current liability	200,848,209	202,254,081
Current liability	1,405,872	1,272,513
<b>Total</b>	<b>202,254,081</b>	<b>203,526,694</b>
<b>11.00 Liabilities for expenses</b>		
Sun Pharmaceutical (Bangladesh) Limited	-	660,527
Salaries Payable	983,156	-
Audit fees payable	50,000	50,000
Trade and other payable	1,263,953	-
TDS payable	357,450	28,097
VDS payable	419,736	49,649
<b>Total</b>	<b>3,074,295</b>	<b>788,273</b>

Amount in Taka	
01 April 2021 to 31 March 2022	25 October 2020 to 31 March 2021

#### 12.00 Operating and other expenses

Audit fees	57,500	57,500
Salaries and Wages	983,156	-
Bank Charges	70,100	-
Professional and legal and consultancy service	1,413,189	-
Office expense	679,622	-
Power and Fuel	53,218	-
Exchange loss/(gain)	66,602	-
Travelling and Conveyance	126,339	-
Miscellaneous expenses	249,265	-
Incorporation expenses	-	660,527
Service charge	-	262,111
<b>Total</b>	<b>3,698,991</b>	<b>980,138</b>

#### 13.00 Financial risk management objective and policies

The managements has overall responsibility for the establishment and oversight of the Company's risk management framework. The Company's risk management policies are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the Company's activities.

The Company has exposure to the following risks from its use of financial instruments:

- Credit risks
- Liquidity risks
- Market risk

##### Credit risk

Credit risk is the risk of a financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the company's receivables from customers.

Management has a credit policy in place and the exposure to credit risk is monitored on an ongoing basis.

##### Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting date was:

Notes	31-Mar-22 Taka	31-Mar-21 Taka
Cash and cash equivalents except cash in hand	7.00 63,529,612	15,937,117
Advances, deposits and prepayments	6.00 83,819,083	35,160,338
<b>Total</b>	<b>147,348,695</b>	<b>51,097,455</b>

To mitigate the credit risk against trade and other receivables, the company has a system of specific credit line period to the parties. This outstanding period and amount are regularly monitored. The Company endeavors to cover the credit risks on all other receivables, where possible, by restricting credit facility and stringent monitoring.

##### Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities. The Company's approach to managing liquidity (cash and bank balances) is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when they fall due, under both normal and stressed conditions, without incurring unacceptable losses.

Typically, the Company ensures that it has sufficient cash and bank balances to meet expected operational expenses, including financial obligations through preparation of the cash flow forecast, based on time line of payment of the financial obligation and accordingly arranging for sufficient liquidity/fund to make the expected payment within due date.

The table below summarises the Company's financial liabilities as at the reporting date.

Notes	31-Mar-22 Taka	31-Mar-21 Taka
Liabilities for expenses	11.00 3,074,295	788,273
	<b>3,074,295</b>	<b>788,273</b>

**Market risk**

Typically, the Company ensures that it has sufficient cash and bank balances to meet expected operational expenses, including financial obligations through preparation of the cash flow forecast, based on time line of payment of the financial obligation and accordingly arranging for sufficient liquidity/fund to make the expected payment within due date.

**Currency risk****Transaction risk**

Transaction risk arises from risk of adverse exchange rate movements occurring in the course of normal international transaction.

**Interest rate risk**

Interest rate risk arises from movement in interest rates. The company needs to manage interest rate risk so as to be able to repay debts as they fall due and to minimise the risks surrounding interest payments and receipts.

**14.00 Related party disclosures****(a) Related party transactions**

As per International Accounting Standards (IAS) 24: "Related Party Disclosures", parties are considered to be related if one of the parties has the ability to control the other party or exercises significant influence over the other party in making financial and operating decisions.

During the year, the company made a number of transactions with related party in the normal course of business. Name of the related party, nature of those transactions and total value have been set out in accordance with the provisions of IAS-24: Related Party Disclosure.

Name of the related party transaction	Nature of transaction	Relationship	Amount in Taka	
			31 March 2022	
			Transaction value	Amount due
Sun Pharmaceutical (Bangladesh) Limited	Loan	Shareholder	220,000,000	220,000,000
			<b>220,000,000</b>	<b>220,000,000</b>

Name of the related party transaction	Nature of transaction	Relationship	Amount in Taka	
			31 March 2021	
			Transaction value	Amount due
Sun Pharmaceutical (Bangladesh) Limited (599,999 ordinary shares @ Tk. 100 each)	Share capital	Shareholder	59,999,900	59,999,900
Mr. Shuvojit Ghosh (1 ordinary share @ Tk. 100 each)	Share capital	Shareholder	100	100
			<b>60,000,000</b>	<b>60,000,000</b>